Recent Updates — EVGN
Evogene Ltd. entered into a cooperation agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. to resolve outstanding differences, resulting in the appointment of Dr. Adi Zuluf-Shani and Mr. Oz Adler as directors. The parties agreed to withdraw a threatened special tender offer and implement a 60-day standstill period for both sides. A special general meeting is scheduled for November 10, 2026, where shareholders will vote on the election of four additional shareholder nominees and approve the agreement itself. Evogene operates in the computational biology and life sciences industry.
Evogene Ltd. received a letter from Nasdaq granting an additional 180-day period to regain compliance with the minimum bid price requirement, extending the deadline to March 29, 2027. The company was previously notified on March 30, 2026, that its closing bid price had been below $1.00 per share for 30 consecutive business days. Evogene can regain compliance if its ordinary shares close at least $1.00 for ten consecutive business days during the cure period. Failure to meet this requirement by March 29, 2027, could result in delisting from Nasdaq. The company intends to consider options such as a reverse share split to address the deficiency. Evogene operates in the computational chemistry industry, specializing in generative AI for small molecule design in pharmaceuticals and agriculture.
Evogene Ltd. reported unaudited financial results for the six months ended June 30, 2026, showing a net loss of $7.7 million compared to $7.7 million in the prior year period. Revenues decreased to approximately $0.7 million from $2.9 million, primarily due to lower seed sales by subsidiary Casterra. The company executed a warrant inducement transaction in February 2026, raising approximately $3.4 million through the exercise of existing warrants at a reduced price and issuing new warrants. Additionally, Evogene raised approximately $3.3 million via an ATM offering with A.G.P./Alliance Global Partner in July and August 2026. The filing notes that dissident shareholders have initiated proceedings under Israeli law following a contested annual meeting on September 4, 2026. Evogene operates in the biotechnology industry, utilizing AI-driven platforms to discover and optimize small molecules for pharmaceutical and agricultural applications.
Following its Annual General Meeting on September 4, 2026, Evogene Ltd. reported that dissident shareholders L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. challenged the voting results and issued notice of intent to launch a special tender offer under Israeli law. Concurrently, directors Yoshinori Oikawa and Dr. Yael Margolin resigned from the board on September 9, 2026, with no stated disagreements regarding company operations or policies. The Company is currently engaging in discussions with these shareholders to resolve the disputes. Evogene Ltd. operates in the biotechnology industry, focusing on drug discovery and development using its proprietary platforms.
Evogene Ltd. reported second quarter and first half 2026 financial results on August 18, 2026. The company reduced its net loss to approximately $1.8 million for the quarter, down from $4.7 million in the prior year period. Cash burn is expected to decline to $8.5–$9.5 million in 2026, compared with $14.4 million in 2025. Evogene raised approximately $11.1 million in new capital since early 2025 and holds $9.3 million in cash as of June 30, 2026. The company expanded its virtual chemical space to 110 billion molecules and integrated autonomous AI Agents via a partnership with Google Cloud. It also established six active drug development collaborations and advanced internal programs toward lead optimization. Evogene operates in the computational chemistry industry, specializing in the generative design of small molecules for pharmaceutical and agricultural applications.